[144] Incyte Genomics Inc SEC Filing
Incyte Genomics' Form 144 discloses a proposed sale of 14,037 common shares with an aggregate market value of $1,122,969.83, to be sold through Morgan Stanley Smith Barney on 08/12/2025 on NASDAQ. The filing states these shares were acquired on 08/12/2025 through a stock option exercise and paid for in cash.
The notice also lists recent sales by BARRY FLANNELLY totaling 13,435 shares in July 2025, generating gross proceeds of $917,923.70. The filing shows 195,276,145 shares outstanding and includes the filer's certification that they do not possess undisclosed material adverse information.
Il Form 144 di Incyte Genomics segnala una proposta di vendita di 14,037 azioni ordinarie per un valore di mercato complessivo di $1,122,969.83, che saranno vendute tramite Morgan Stanley Smith Barney il 08/12/2025 sul NASDAQ. Il documento dichiara che queste azioni sono state acquisite il 08/12/2025 mediante un esercizio di opzione su azioni e pagate in contanti.
La comunicazione riporta inoltre vendite recenti di BARRY FLANNELLY per un totale di 13,435 azioni a luglio 2025, con proventi lordi pari a $917,923.70. Il deposito indica 195,276,145 azioni in circolazione e include la certificazione del dichiarante di non essere in possesso di informazioni materiali sfavorevoli non divulgate.
El Formulario 144 de Incyte Genomics revela una propuesta de venta de 14,037 acciones comunes por un valor de mercado agregado de $1,122,969.83, que se vender谩n a trav茅s de Morgan Stanley Smith Barney el 08/12/2025 en NASDAQ. La presentaci贸n indica que estas acciones fueron adquiridas el 08/12/2025 mediante un ejercicio de opci贸n sobre acciones y pagadas en efectivo.
El aviso tambi茅n enumera ventas recientes de BARRY FLANNELLY que suman 13,435 acciones en julio de 2025, generando ingresos brutos de $917,923.70. La presentaci贸n muestra 195,276,145 acciones en circulaci贸n e incluye la certificaci贸n del declarante de que no posee informaci贸n material adversa no divulgada.
Incyte Genomics鞚� Form 144電� 齑� 鞁滌灔 臧�旃橁皜 $1,122,969.83鞚� 14,037 氤错喌欤� 毵り皝 鞓堨爼 靷嫟鞚� 瓿奠嫓頄堨溂氅�, 頃措嫻 欤检嫕鞚� 08/12/2025鞐� Morgan Stanley Smith Barney毳� 韱淀暣 NASDAQ鞐愳劀 毵る弰霅� 鞓堨爼鞛呺媹雼�. 鞝滌稖靹滊電� 頃措嫻 欤检嫕鞚� 08/12/2025鞐� 鞀ろ啞鞓奠厴 頄夓偓搿� 旆摑霅橃棃瓿� 順勱笀鞙茧 瓴办牅霅橃棃雼り碃 氇呾嫓頃╇媹雼�.
鞚� 韱奠電� 霕愴暅 BARRY FLANNELLY臧� 2025雲� 7鞗旍棎 齑� 13,435欤�毳� 斓滉芳 毵る弰頃橃棳 齑濍Г於滌暋 $917,923.70毳� 氚滌儩鞁滌及雼り碃 旮办灛頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 195,276,145欤检潣 鞙犿喌欤检嫕 靾橁皜 旮办灛霅橃柎 鞛堨溂氅�, 鞝滌稖鞛愱皜 氙戈车臧� 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 鞚胳頃橂姅 雮挫毄霃� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Le Form 144 d'Incyte Genomics r茅v猫le une vente propos茅e de 14,037 actions ordinaires pour une valeur marchande globale de $1,122,969.83, devant 锚tre vendues via Morgan Stanley Smith Barney le 08/12/2025 sur le NASDAQ. Le d茅p么t indique que ces actions ont 茅t茅 acquises le 08/12/2025 par exercice d'options sur actions et pay茅es en esp猫ces.
L'avis mentionne 茅galement des ventes r茅centes effectu茅es par BARRY FLANNELLY totalisant 13,435 actions en juillet 2025, g茅n茅rant des produits bruts de $917,923.70. Le dossier fait 茅tat de 195,276,145 actions en circulation et inclut la certification du d茅clarant qu'il ne d茅tient pas d'informations d茅favorables importantes non divulgu茅es.
Das Form 144 von Incyte Genomics offenbart einen geplanten Verkauf von 14,037 Stammaktien mit einem Gesamtmarktwert von $1,122,969.83, der am 08/12/2025 眉产别谤 Morgan Stanley Smith Barney an der NASDAQ erfolgen soll. Die Einreichung gibt an, dass diese Aktien am 08/12/2025 durch eine Aus眉bung von Aktienoptionen erworben und bar bezahlt wurden.
Die Mitteilung listet au脽erdem j眉ngste Verk盲ufe von BARRY FLANNELLY mit insgesamt 13,435 Aktien im Juli 2025 auf, die Bruttoerl枚se von $917,923.70 erzielten. Die Einreichung weist 195,276,145 ausstehende Aktien aus und enth盲lt die Best盲tigung des Einreichenden, dass ihm keine unoffengelegten wesentlichen nachteiligen Informationen vorliegen.
- None.
- None.
Insights
TL;DR: Insider filed to sell 14,037 shares (~$1.12M); July dispositions totaled 13,435 shares (~$917.9k); impact appears limited relative to outstanding shares.
The Form 144 provides standard disclosure of a proposed sale, identifying the broker, share count, aggregate market value, and the fact the shares were acquired via stock option exercise and paid in cash. Recent July sales by the named seller are itemized with dates and gross proceeds. Taken together, these filings document insider liquidity actions but do not, by themselves, change the companys reported outstanding share count or financials in this notice.
TL;DR: Filing shows compliance with Rule 144 and transparency on option exercise and subsequent sales; monitor for continued insider activity.
The document lists the broker and provides transaction-level details, including acquisition method (stock option exercise) and payment type (cash), which supports disclosure compliance. The filer also affirms no undisclosed material adverse information. The record of multiple sales over recent weeks is factual and warrants routine governance monitoring but is not presented here as a regulatory or disclosure failure.
Il Form 144 di Incyte Genomics segnala una proposta di vendita di 14,037 azioni ordinarie per un valore di mercato complessivo di $1,122,969.83, che saranno vendute tramite Morgan Stanley Smith Barney il 08/12/2025 sul NASDAQ. Il documento dichiara che queste azioni sono state acquisite il 08/12/2025 mediante un esercizio di opzione su azioni e pagate in contanti.
La comunicazione riporta inoltre vendite recenti di BARRY FLANNELLY per un totale di 13,435 azioni a luglio 2025, con proventi lordi pari a $917,923.70. Il deposito indica 195,276,145 azioni in circolazione e include la certificazione del dichiarante di non essere in possesso di informazioni materiali sfavorevoli non divulgate.
El Formulario 144 de Incyte Genomics revela una propuesta de venta de 14,037 acciones comunes por un valor de mercado agregado de $1,122,969.83, que se vender谩n a trav茅s de Morgan Stanley Smith Barney el 08/12/2025 en NASDAQ. La presentaci贸n indica que estas acciones fueron adquiridas el 08/12/2025 mediante un ejercicio de opci贸n sobre acciones y pagadas en efectivo.
El aviso tambi茅n enumera ventas recientes de BARRY FLANNELLY que suman 13,435 acciones en julio de 2025, generando ingresos brutos de $917,923.70. La presentaci贸n muestra 195,276,145 acciones en circulaci贸n e incluye la certificaci贸n del declarante de que no posee informaci贸n material adversa no divulgada.
Incyte Genomics鞚� Form 144電� 齑� 鞁滌灔 臧�旃橁皜 $1,122,969.83鞚� 14,037 氤错喌欤� 毵り皝 鞓堨爼 靷嫟鞚� 瓿奠嫓頄堨溂氅�, 頃措嫻 欤检嫕鞚� 08/12/2025鞐� Morgan Stanley Smith Barney毳� 韱淀暣 NASDAQ鞐愳劀 毵る弰霅� 鞓堨爼鞛呺媹雼�. 鞝滌稖靹滊電� 頃措嫻 欤检嫕鞚� 08/12/2025鞐� 鞀ろ啞鞓奠厴 頄夓偓搿� 旆摑霅橃棃瓿� 順勱笀鞙茧 瓴办牅霅橃棃雼り碃 氇呾嫓頃╇媹雼�.
鞚� 韱奠電� 霕愴暅 BARRY FLANNELLY臧� 2025雲� 7鞗旍棎 齑� 13,435欤�毳� 斓滉芳 毵る弰頃橃棳 齑濍Г於滌暋 $917,923.70毳� 氚滌儩鞁滌及雼り碃 旮办灛頃橁碃 鞛堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 195,276,145欤检潣 鞙犿喌欤检嫕 靾橁皜 旮办灛霅橃柎 鞛堨溂氅�, 鞝滌稖鞛愱皜 氙戈车臧� 欷戨寑頃� 攵堧Μ頃� 鞝曤炒臧� 鞐嗢潓鞚� 鞚胳頃橂姅 雮挫毄霃� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Le Form 144 d'Incyte Genomics r茅v猫le une vente propos茅e de 14,037 actions ordinaires pour une valeur marchande globale de $1,122,969.83, devant 锚tre vendues via Morgan Stanley Smith Barney le 08/12/2025 sur le NASDAQ. Le d茅p么t indique que ces actions ont 茅t茅 acquises le 08/12/2025 par exercice d'options sur actions et pay茅es en esp猫ces.
L'avis mentionne 茅galement des ventes r茅centes effectu茅es par BARRY FLANNELLY totalisant 13,435 actions en juillet 2025, g茅n茅rant des produits bruts de $917,923.70. Le dossier fait 茅tat de 195,276,145 actions en circulation et inclut la certification du d茅clarant qu'il ne d茅tient pas d'informations d茅favorables importantes non divulgu茅es.
Das Form 144 von Incyte Genomics offenbart einen geplanten Verkauf von 14,037 Stammaktien mit einem Gesamtmarktwert von $1,122,969.83, der am 08/12/2025 眉产别谤 Morgan Stanley Smith Barney an der NASDAQ erfolgen soll. Die Einreichung gibt an, dass diese Aktien am 08/12/2025 durch eine Aus眉bung von Aktienoptionen erworben und bar bezahlt wurden.
Die Mitteilung listet au脽erdem j眉ngste Verk盲ufe von BARRY FLANNELLY mit insgesamt 13,435 Aktien im Juli 2025 auf, die Bruttoerl枚se von $917,923.70 erzielten. Die Einreichung weist 195,276,145 ausstehende Aktien aus und enth盲lt die Best盲tigung des Einreichenden, dass ihm keine unoffengelegten wesentlichen nachteiligen Informationen vorliegen.
FAQ
What does INCY's Form 144 disclose?
How were the 14,037 INCY shares acquired?
Has the insider sold INCY shares recently?
What is the company's reported share count in this notice?
Does the filer state any undisclosed material information?
